Phase 4
Completed N=40
Fibrinolysis Before Cardiopulmonary Bypass?
Pathologic Fibrinolysis
Source: ClinicalTrials.gov NCT01981863 ↗
Enrolled (actual)
40
Serious AEs
0.0%
Results posted
Jun 2016
Primary outcomePrimary: Di-Dimer Increase Before Cardiopulmonary Bypass — 317; 266; 317; 291 ng/mL
◆ Published Evidence
No publication linked
No peer-reviewed publication reporting this trial's results has been linked yet. This can indicate results are unpublished — a known publication-bias signal. We re-check periodically.
Summary
It is common practice to use antifibrinolytic agents before and during cardiopulmonary bypass. They are not without side effects. The investigators want to show that there is no proof of fibrinolysis in standard sternotomy cardiac surgery patients before cardiopulmonary bypass, and that antifibrinolytic agents should only be started on cardiopulmonary bypass.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Di-Dimer Increase Before Cardiopulmonary Bypass |
317; 266; 317; 291; 537; 911 | — |
| SECONDARY Value of Thromboelastography as Monitor of Fibrinolysis |
0; 0; 0; 0; 0; 0 | — |
Eligibility Criteria
Inclusion Criteria
- All adult patients, undergoing first time sternotomy for Coronary artery bypass grafting/Aortic valve replacement/aortic surgery
Exclusion Criteria
- Resternotomy, renal insufficiency, deep hypothermia, age < 18 yrs
Data sourced from ClinicalTrials.gov (NCT01981863). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.